Larimar Therapeutics (LRMR) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.99, -0.25% vs the prior close of $1.99.
- Volume 1.69M shares, 1.3x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
LRMR ends flat (-0.3%) to $1.99, a 52-week low, 12 down days in a row. Closed at $1.99, -0.25% vs the prior close of $1.99. Day range $1.91–$2.07, opened at $2.05.
LRMR daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — LRMR ends flat (-0.3%) to $1.99, a 52-week low, 12 down days in a row
- Closed at $1.99, -0.25% vs the prior close of $1.99. Day range $1.91–$2.07, opened at $2.05.
- Volume was 1.69M shares, 1.3x its 50-day average of 1.31M.
- Price is -44.6% vs its 50-day average ($3.58) and -48.6% vs its 200-day average ($3.86).
- 52-week range $1.91–$6.42; today's close sits at 2% of that range, 69.1% below the 52-week high.
- That makes 12 straight losses.
Oct 15, 2026 — LRMR slides 4.8% to $1.99, a 52-week low on 5.1x normal volume
- Closed at $1.99, -4.78% vs the prior close of $2.09. Day range $1.95–$2.12, opened at $2.09.
- Volume was 6.17M shares, 5.1x its 50-day average of 1.21M — unusually heavy trading.
- Price is -45.1% vs its 50-day average ($3.63) and -48.6% vs its 200-day average ($3.87).
- 52-week range $1.95–$6.42; today's close sits at 1% of that range, 69.0% below the 52-week high.
- That makes 11 straight losses.
Oct 14, 2026 — LRMR slides 3.2% to $2.09, a 52-week low on 1.9x normal volume
- Closed at $2.09, -3.24% vs the prior close of $2.16. Day range $2.06–$2.22, opened at $2.15.
- Volume was 2.26M shares, 1.9x its 50-day average of 1.20M — unusually heavy trading.
- Price is -43.0% vs its 50-day average ($3.67) and -46.1% vs its 200-day average ($3.88).
- 52-week range $2.06–$6.42; today's close sits at 1% of that range, 67.4% below the 52-week high.
- That makes 10 straight losses.
Oct 13, 2026 — LRMR slides 14.6% to $2.16, a 52-week low on 2.2x normal volume
- Closed at $2.16, -14.62% vs the prior close of $2.53. Day range $2.13–$2.53, opened at $2.53.
- Volume was 2.57M shares, 2.2x its 50-day average of 1.16M — unusually heavy trading.
- Price is -41.7% vs its 50-day average ($3.71) and -44.4% vs its 200-day average ($3.89).
- 52-week range $2.13–$6.42; today's close sits at 1% of that range, 66.4% below the 52-week high.
- That makes 9 straight losses.
Oct 12, 2026 — LRMR slides 5.2% to $2.53, a 52-week low, 8 down days in a row
- Closed at $2.53, -5.24% vs the prior close of $2.67. Day range $2.53–$2.69, opened at $2.66.
- Volume was 950.20K shares, 0.8x its 50-day average of 1.17M.
- Price is -32.4% vs its 50-day average ($3.74) and -35.1% vs its 200-day average ($3.90).
- 52-week range $2.53–$6.42; today's close sits at 0% of that range, 60.6% below the 52-week high.
- That makes 8 straight losses.
Oct 9, 2026 — LRMR dips 1.1% to $2.67, a 52-week low, 7 down days in a row
- Closed at $2.67, -1.11% vs the prior close of $2.70. Day range $2.62–$2.74, opened at $2.68.
- Volume was 867.60K shares, 0.7x its 50-day average of 1.17M.
- Price is -29.2% vs its 50-day average ($3.77) and -31.6% vs its 200-day average ($3.90).
- 52-week range $2.61–$6.42; today's close sits at 2% of that range, 58.4% below the 52-week high.
- That makes 7 straight losses.
Oct 8, 2026 — LRMR dips 1.8% to $2.70, a 52-week low, 6 down days in a row
- Closed at $2.70, -1.82% vs the prior close of $2.75. Day range $2.61–$2.74, opened at $2.72.
- Volume was 1.19M shares, 1.0x its 50-day average of 1.18M.
- Price is -28.8% vs its 50-day average ($3.79) and -31.0% vs its 200-day average ($3.91).
- 52-week range $2.61–$6.42; today's close sits at 2% of that range, 57.9% below the 52-week high.
- That makes 6 straight losses.
Oct 7, 2026 — LRMR dips 1.1% to $2.75, a 52-week low, 5 down days in a row
- Closed at $2.75, -1.08% vs the prior close of $2.78. Day range $2.72–$2.84, opened at $2.77.
- Volume was 718.00K shares, 0.6x its 50-day average of 1.20M — lighter than usual.
- Price is -27.9% vs its 50-day average ($3.81) and -29.8% vs its 200-day average ($3.91).
- 52-week range $2.71–$6.42; today's close sits at 1% of that range, 57.2% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — LRMR dips 2.8% to $2.78, a 52-week low, 4 down days in a row
- Closed at $2.78, -2.80% vs the prior close of $2.86. Day range $2.74–$2.90, opened at $2.88.
- Volume was 828.10K shares, 0.7x its 50-day average of 1.22M.
- Price is -27.5% vs its 50-day average ($3.83) and -29.1% vs its 200-day average ($3.92).
- 52-week range $2.71–$6.42; today's close sits at 2% of that range, 56.7% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — LRMR slides 3.4% to $2.86, a 6-month low, 3 down days in a row
- Closed at $2.86, -3.38% vs the prior close of $2.96. Day range $2.78–$3.04, opened at $2.96.
- Volume was 886.00K shares, 0.7x its 50-day average of 1.23M.
- Price is -25.8% vs its 50-day average ($3.85) and -27.1% vs its 200-day average ($3.92).
- 52-week range $2.71–$6.42; today's close sits at 4% of that range, 55.5% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — LRMR slides 3.3% to $2.96, a 6-month low
- Closed at $2.96, -3.27% vs the prior close of $3.06. Day range $2.92–$3.11, opened at $3.11.
- Volume was 835.00K shares, 0.7x its 50-day average of 1.23M.
- Price is -23.7% vs its 50-day average ($3.88) and -24.6% vs its 200-day average ($3.93).
- 52-week range $2.71–$6.42; today's close sits at 7% of that range, 53.9% below the 52-week high.
LRMR latest news & SEC filings
Every SEC filing by or about LRMR in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Harlow John B. Jr. received an award of 50,000 shares on Sep 29, 2026; now holds 50,000
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 4, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$32.78M (prior year -$26.18M) (loss widened vs Jun 30, 2025)
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 8.01 — Reported other events the company considers important.
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hamilton Thomas Edward bought 50,000 shares at $3.34 (≈$167.00K) on Jul 6, 2026
- Hamilton Thomas Edward bought 50,000 shares at $3.34 (≈$167.00K) on Jul 6, 2026
- Hamilton Thomas Edward bought 50,000 shares at $3.34 (≈$167.00K) on Jul 6, 2026
- Hamilton Thomas Edward bought 50,000 shares at $3.34 (≈$167.00K) on Jul 6, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jun 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade LRMR
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Mar 19, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.78% (largest 14.6%). That is a volatile stock.
- Liquidity: about 1.74M shares (≈$3.45M) trade per day on average.
- 52-week position: $1.99 vs a range of $1.91–$6.42 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Thomas Edward Hamilton bought 50,000 shares on Jul 6, 2026.
- Latest filings: 8-K Sep 29, 2026; 10-Q Aug 4, 2026; 8-K Aug 4, 2026.
- Share count: 103.88M shares outstanding (Aug 2, 2026), +21.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
LRMR market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.05 | 2.07 | 1.91 | 1.99 | 1.69M |
| Oct 15, 2026 | 2.09 | 2.12 | 1.95 | 1.99 | 6.17M |
| Oct 14, 2026 | 2.15 | 2.22 | 2.06 | 2.09 | 2.26M |
| Oct 13, 2026 | 2.53 | 2.53 | 2.13 | 2.16 | 2.57M |
| Oct 12, 2026 | 2.66 | 2.69 | 2.53 | 2.53 | 950.20K |
| Oct 9, 2026 | 2.68 | 2.74 | 2.62 | 2.67 | 867.60K |
| Oct 8, 2026 | 2.72 | 2.74 | 2.61 | 2.70 | 1.19M |
| Oct 7, 2026 | 2.77 | 2.84 | 2.72 | 2.75 | 718.00K |
| Oct 6, 2026 | 2.88 | 2.90 | 2.74 | 2.78 | 828.10K |
| Oct 5, 2026 | 2.96 | 3.04 | 2.78 | 2.86 | 886.00K |
| Oct 2, 2026 | 3.11 | 3.11 | 2.92 | 2.96 | 835.00K |
| Oct 1, 2026 | 3.20 | 3.20 | 3.04 | 3.06 | 858.30K |
| Sep 30, 2026 | 3.13 | 3.22 | 3.08 | 3.19 | 1.50M |
| Sep 29, 2026 | 3.13 | 3.20 | 3.12 | 3.14 | 1.04M |
| Sep 28, 2026 | 3.04 | 3.23 | 3.03 | 3.17 | 1.67M |
| Sep 25, 2026 | 3.32 | 3.34 | 3.02 | 3.08 | 3.05M |
| Sep 24, 2026 | 3.85 | 3.86 | 3.31 | 3.32 | 3.63M |
| Sep 23, 2026 | 3.82 | 3.90 | 3.71 | 3.87 | 2.72M |
| Sep 22, 2026 | 3.91 | 3.96 | 3.82 | 3.82 | 702.90K |
| Sep 21, 2026 | 3.84 | 3.88 | 3.78 | 3.83 | 578.00K |
About Larimar Therapeutics
Larimar Therapeutics (LRMR) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BALA CYNWYD, PA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1374690.
LRMR board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Carole Ben-Maimon | President and CEO | Jan 27, 2026 |
| Management Company, L.P. Deerfield | * Director by Deputization | May 20, 2026 |
| Partners, L.P. Deerfield | * Director by Deputization | Mar 2, 2026 |
| Healthcare Innovations Fund, L.P. Deerfield | * Director by Deputization | Mar 2, 2026 |
| Mgmt Hif, L.P. Deerfield | * Director by Deputization | Mar 2, 2026 |
| Mgmt Iii, L.P. Deerfield | * Director by Deputization | Mar 2, 2026 |
| Mgmt Iv, L.P. Deerfield | * Director by Deputization | Mar 2, 2026 |
| Mgmt L.P. Deerfield | * Director by Deputization | Mar 2, 2026 |
| Private Design Fund Iii, L.P. Deerfield | * Director by Deputization | Mar 2, 2026 |
| Private Design Fund Iv, L.P. Deerfield | * Director by Deputization | Mar 2, 2026 |
| James E Flynn | * Director by Deputization | May 20, 2026 |
| Thomas Edward Hamilton | Director | Jul 8, 2026 |
| Jonathan S Leff | Director | May 20, 2026 |
| Jeffrey W Sherman | Director | May 20, 2026 |
| Frank E Thomas | Director | May 20, 2026 |
| Joseph Truitt | Director | May 20, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Carole Ben-Maimon | President and CEO | Jan 27, 2026 |
| Michael Celano | Chief Financial Officer | Jan 27, 2026 |
| Russell Clayton | Chief Medical Officer | Jan 27, 2026 |
| Gopi Shankar | Chief Development Officer | Jan 27, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 6, 2026 | Thomas Edward Hamilton | Buy | 50,000 | $3.34 |
| Jul 6, 2026 | Thomas Edward Hamilton | Buy | 50,000 | $3.34 |
| Jul 6, 2026 | Thomas Edward Hamilton | Buy | 50,000 | $3.34 |
| Jul 6, 2026 | Thomas Edward Hamilton | Buy | 50,000 | $3.34 |
| Feb 27, 2026 | Mgmt Hif, L.P. Deerfield | Buy | 1,084,010 | $5.00 |
| Feb 27, 2026 | Mgmt Hif, L.P. Deerfield | Buy | 2,000,000 | $5.00 |
| Feb 27, 2026 | Mgmt Hif, L.P. Deerfield | Buy | 831,978 | $5.00 |
| Feb 27, 2026 | Mgmt Hif, L.P. Deerfield | Buy | 1,084,012 | $5.00 |
| Feb 27, 2026 | Mgmt Hif, L.P. Deerfield | Buy | 1,084,010 | $5.00 |
| Feb 27, 2026 | Mgmt Hif, L.P. Deerfield | Buy | 2,000,000 | $5.00 |
| Feb 27, 2026 | Mgmt Hif, L.P. Deerfield | Buy | 831,978 | $5.00 |
| Feb 27, 2026 | Mgmt Hif, L.P. Deerfield | Buy | 1,084,012 | $5.00 |
| Feb 27, 2026 | Mgmt L.P. Deerfield | Buy | 1,084,010 | $5.00 |
| Feb 27, 2026 | Mgmt L.P. Deerfield | Buy | 2,000,000 | $5.00 |
| Feb 27, 2026 | Mgmt L.P. Deerfield | Buy | 831,978 | $5.00 |
LRMR financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-165.67M | — | $-113.20M |
| Dec 31, 2024 | — | $-80.60M | -1.32 | $-70.76M |
| Dec 31, 2023 | — | $-36.95M | -0.84 | $-33.46M |
| Dec 31, 2022 | — | $-35.35M | -1.37 | $-27.57M |
| Dec 31, 2021 | — | $-50.64M | -2.95 | $-42.10M |
Latest balance sheet: total assets $165.30M, total liabilities $37.92M, cash $92.69M (as of Jun 30, 2026).
LRMR earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $4.11 |
| May 14, 2026 | 8-K Item 2.02 (results) | $3.89 |
| Mar 19, 2026 | 8-K Item 2.02 (results) | $4.47 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $3.25 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $3.22 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $4.26 |
| Jul 29, 2025 | 8-K Item 2.02 (results) | $3.53 |
| Apr 30, 2025 | 8-K Item 2.02 (results) | $2.65 |
| Mar 24, 2025 | 8-K Item 2.02 (results) | $2.28 |
| Oct 30, 2024 | 8-K Item 2.02 (results) | $8.46 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on LRMR
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.